King's College London

Research portal

Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy

Research output: Contribution to journalArticle

Madeleine Duvic, Susan E. Bates, Richard Piekarz, Robin Eisch, Youn H. Kim, Adam Lerner, Tadeusz Robak, Alexey Samtsov, Jürgen C. Becker, William McCulloch, Joel Waksman, Sean Whittaker

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalLeukemia and Lymphoma
Early online date30 Aug 2017
Accepted/In press22 Jul 2017
E-pub ahead of print30 Aug 2017

King's Authors


Cutaneous T-cell lymphomas (CTCL) are a group of non-Hodgkin lymphomas that typically present in the skin but can progress to systemic involvement. The optimal treatment for patients who relapse from or are refractory to systemic chemotherapy remains unclear. Romidepsin is a potent, class-I selective histone deacetylase inhibitor approved for the treatment of patients with CTCL who have had ≥1 prior systemic therapy. Here, we present a subanalysis of two phase-2 trials (NCT00106431, NCT00007345) of romidepsin in patients with CTCL who had prior treatment with systemic chemotherapy. Patients with prior chemotherapy were able to achieve durable responses to romidepsin, and response rates were similar to those in patients who were chemotherapy naïve. Overall, no new safety signals emerged in patients who had received prior chemotherapy. The data presented here suggest that romidepsin is safe and effective in patients with CTCL who received prior systemic chemotherapy.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454